Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vivek Subbiah

Showing results (371-380 of 487) with videos related to

Pageof 49
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2014
Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinicChad Tang, Kenneth Hess, Denis Leonardo F Jardim, et al.
Investigational New Drugs|October 20, 2017
Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancerShumei Kato, Denis L Jardim, Faye M Johnson, et al.
Frontiers in Oncology|May 8, 2026
Phase II study of magrolimab combined with docetaxel in previously treated metastatic advanced solid tumorsAntoine Italiano, Teresa García Manrique, Enrique Grande Pulido, et al.
Investigational New Drugs|April 28, 2021
Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib studyKyaw Zin Thein, Sarina A Piha-Paul, Apostolia Tsimberidou, et al.
The Oncologist|March 30, 2021
Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical TrialsRyan W Huey, Goldy C George, Penny Phillips, et al.
The Lancet. Oncology|August 21, 2020
Dabrafenib plus trametinib in patients with BRAF<sup>V600E</sup>-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trialVivek Subbiah, Ulrik Lassen, Elena Élez, et al.
Cancer Research|May 20, 2016
Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center StudyJennifer J Wheler, Filip Janku, Aung Naing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2020
Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-positive Metastatic Breast Cancer or Other Solid TumorsAlexej Ballhausen, Jennifer J Wheler, Daniel D Karp, et al.
Cancer Medicine|November 25, 2016
Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experienceZhijie Wang, Naiyi Shi, Aung Naing, et al.
Scientific Reports|October 18, 2016
Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved TherapiesVivek Subbiah, Kenneth R Hess, Muhammad Rizwan Khawaja, et al.
Pageof 49

Showing results (371-380 of 487) with videos related to

Sort By:
Pageof 49
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2014
Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinicChad Tang, Kenneth Hess, Denis Leonardo F Jardim, et al.
Investigational New Drugs|October 20, 2017
Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancerShumei Kato, Denis L Jardim, Faye M Johnson, et al.
Frontiers in Oncology|May 8, 2026
Phase II study of magrolimab combined with docetaxel in previously treated metastatic advanced solid tumorsAntoine Italiano, Teresa García Manrique, Enrique Grande Pulido, et al.
Investigational New Drugs|April 28, 2021
Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib studyKyaw Zin Thein, Sarina A Piha-Paul, Apostolia Tsimberidou, et al.
The Oncologist|March 30, 2021
Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical TrialsRyan W Huey, Goldy C George, Penny Phillips, et al.
The Lancet. Oncology|August 21, 2020
Dabrafenib plus trametinib in patients with BRAF<sup>V600E</sup>-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trialVivek Subbiah, Ulrik Lassen, Elena Élez, et al.
Cancer Research|May 20, 2016
Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center StudyJennifer J Wheler, Filip Janku, Aung Naing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2020
Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-positive Metastatic Breast Cancer or Other Solid TumorsAlexej Ballhausen, Jennifer J Wheler, Daniel D Karp, et al.
Cancer Medicine|November 25, 2016
Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experienceZhijie Wang, Naiyi Shi, Aung Naing, et al.
Scientific Reports|October 18, 2016
Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved TherapiesVivek Subbiah, Kenneth R Hess, Muhammad Rizwan Khawaja, et al.
Pageof 49